These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 2673457)
1. In vivo infusion of anti LFA-1 antibody in HLA non-identical bone marrow transplantation in children: serum concentrations and biological effects. Perez N; Le Deist F; Chatenoud L; Chanteloup N; Griscelli C; Fischer A Bone Marrow Transplant; 1989 Jul; 4(4):379-84. PubMed ID: 2673457 [TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367 [TBL] [Abstract][Full Text] [Related]
3. Reduction of graft failure by a monoclonal antibody (anti-LFA-1 CD11a) after HLA nonidentical bone marrow transplantation in children with immunodeficiencies, osteopetrosis, and Fanconi's anemia: a European Group for Immunodeficiency/European Group for Bone Marrow Transplantation report. Fischer A; Friedrich W; Fasth A; Blanche S; Le Deist F; Girault D; Veber F; Vossen J; Lopez M; Griscelli C Blood; 1991 Jan; 77(2):249-56. PubMed ID: 1985691 [TBL] [Abstract][Full Text] [Related]
4. Prevention of bone marrow and cardiac graft rejection in an H-2 haplotype disparate mouse combination by an anti-LFA-1 antibody. Cavazzana-Calvo M; Sarnacki S; Haddad E; De Coene C; Calise D; Yvon E; Cerf-Bensussan N; Fischer A Transplantation; 1995 Jun; 59(11):1576-82. PubMed ID: 7778173 [TBL] [Abstract][Full Text] [Related]
5. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient]. Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503 [TBL] [Abstract][Full Text] [Related]
6. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease. Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439 [TBL] [Abstract][Full Text] [Related]
7. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [TBL] [Abstract][Full Text] [Related]
8. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants. Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909 [TBL] [Abstract][Full Text] [Related]
9. Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. Bozdech MJ; Sondel PM; Trigg ME; Longo W; Kohler PC; Flynn B; Billing R; Anderson SA; Hank JA; Hong R Exp Hematol; 1985 Dec; 13(11):1201-10. PubMed ID: 3905427 [TBL] [Abstract][Full Text] [Related]
10. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran. Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149 [TBL] [Abstract][Full Text] [Related]
11. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment. Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810 [TBL] [Abstract][Full Text] [Related]
12. In vivo infusion of anti-LFA-1 and anti-CD2 antibodies prevents graft failure after HLA partially incompatible bone marrow transplantation in children with high risk acute lymphoblastic leukaemia. Cavazzana-Calvo M; Jabado N; Bordigoni P; Michel G; Haddad E; Mechinaud F; Landman-Parker J; Leblanc T; Plouvier E; Baruchel A; Stephan JL; Souillet G; Vilmer E; Wijdenes J; Le Deist F; Fischer A Leuk Lymphoma; 1997 Dec; 28(1-2):103-12. PubMed ID: 9498709 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. Patel NC; Chinen J; Rosenblatt HM; Hanson IC; Brown BS; Paul ME; Abramson SL; Ritz J; Shearer WT J Allergy Clin Immunol; 2008 Dec; 122(6):1185-93. PubMed ID: 19084111 [TBL] [Abstract][Full Text] [Related]
14. Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT). Kedar E; Or R; Naparstek E; Zeira E; Slavin S Bone Marrow Transplant; 1988 Mar; 3(2):129-40. PubMed ID: 3048477 [TBL] [Abstract][Full Text] [Related]
15. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation. Russell CA Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic bone marrow transplantation: relation between chimaerism and immunity. Vossen J Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764 [TBL] [Abstract][Full Text] [Related]
17. Donor-HLA-incompatible marrow transplantation with an anti-donor cytotoxic antibody in the serum of the patient. Maruta A; Fukawa H; Kanamori H; Harano H; Noguchi T; Kodama F; Kase N; Matsuzaki M; Miyashita H; Motomura S Bone Marrow Transplant; 1991 May; 7(5):397-400. PubMed ID: 2070151 [TBL] [Abstract][Full Text] [Related]
18. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1. Ferrant A; Latinne D; Bazin H; Straetmans N; Cornet A; de la Parra B; Michaux JL Bone Marrow Transplant; 1995 Oct; 16(4):577-81. PubMed ID: 8528175 [TBL] [Abstract][Full Text] [Related]
19. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087 [TBL] [Abstract][Full Text] [Related]
20. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]